The Medicines Company (MDCO) stock prices updated...

The Medicines Company stock price, MDCO

The Medicines Company stock chart:

The Medicines Company close price: 47.46

Stock price forecast:

UP TO +0.34%
Target: 47.62

Total forecasts: 90
Reached: 6 (6.67%)

Total Win: 1.41 (3.00%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%

Showing 1-10 of 624 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date

The Medicines Company latest news:

  • 07/05/2017 15:39:05

    UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths

    July 5 (Reuters) - Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.

  • 06/12/2017 10:51:12

    UPDATE 4-U.S. Supreme Court speeds copycat biologic drugs to market

    WASHINGTON, June 12 (Reuters) - The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies.

  • 05/19/2017 15:09:19

    BRIEF-Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

    * Medicines-U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

  • 05/10/2017 15:55:25

    UPDATE 1-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer

    May 10 (Reuters) - Merck & Co said on Wednesday U.S. health regulators approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer, solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer.

  • 05/02/2017 05:54:47

    Merck tops Street 1Q forecasts on cost cuts, new drug sales

    Another round of strong cost-cutting, surging sales of its two newest medicines and a rare strong performance across its entire vaccine portfolio lifted Merck & Co.'s first-quarter results above Wall Street expectations, the company

  • More trends:

    The Michaels Companies, Inc.MIK | The Middleby CorporationMIDD | The Navigators Group, Inc.NAVG | The ONE Group Hospitality, Inc.STKS | The Priceline Group Inc. PCLN | The Providence Service CorporationPRSC | The Spectranetics CorporationSPNC | The Ultimate Software Group, Inc.ULTI | The York Water CompanyYORW | The9 LimitedNCTY |